A Relation of Morphine-induced Itch and Pain Processing
NCT04115462 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2020-07-08
Summary
In This experiment, the investigators would like to test the two following hypotheses regarding the mechanisms by which opioids cause itch:
1. Opioids cause itch by a spinal disinhibition mechanism (central nervous system (CNS) effect).
2. Opioids cause itch through a mast cell-destabilizing effect leading to release of histamine and tryptase in the skin where itch is evoked (peripheral mechanism).
Conditions
- Morphine
- Itch
Interventions
- DRUG
-
Morphine
A 20 mg tablet of morphine
- DRUG
-
Placebo oral tablet
Matching tablet of placebo
- DRUG
-
Histamine
Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
- DRUG
-
Cowhage (Mucuna Pruriens)
25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
- DRUG
-
isotonic saline
A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
- DRUG
-
Histamine
Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
- DRUG
-
Cowhage (Mucuna Pruriens)
25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Sponsors & Collaborators
-
Aalborg University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-01-15
- Primary Completion
- 2020-05-01
- Completion
- 2020-07-07
Countries
- Denmark
Study Locations
More Related Trials
-
Adding Nalbuphine for Control of Intrathecal Morphine Pruritus
NCT04589429 ·Status: UNKNOWN ·Phase: PHASE2
-
Intrathecal Morphine Microdose Method Sensory Changes
NCT03395275 ·Status: WITHDRAWN ·Phase: NA
-
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
NCT05235191 ·Status: COMPLETED ·Phase: PHASE3
-
Role of the Endogenous Opioid System Underlying Modulation of Experimental Pain
NCT01327326 ·Status: WITHDRAWN ·Phase: NA
-
Side Effects of a Single Shot Intrathecal Morphine in Clinical Practice, a Retrospective Analysis
NCT07238179 ·Status: ACTIVE_NOT_RECRUITING
-
Brain Effects of Opiate Agonist and Antagonist
NCT04342130 ·Status: COMPLETED ·Phase: PHASE4
-
Brain Response to Pain Control in People With Chronic Pain
NCT01878019 ·Status: COMPLETED
-
An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain
NCT01112267 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain
NCT00226421 ·Status: COMPLETED ·Phase: PHASE3
-
Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients
NCT01263652 ·Status: WITHDRAWN ·Phase: NA
-
Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia
NCT00218374 ·Status: COMPLETED ·Phase: NA
-
Dextromethorphan Effect on Central Sensitization to Pain in Healthy Volunteers
NCT02596360 ·Status: COMPLETED ·Phase: PHASE1
-
Pain Responses in Patients on Long-Term Opioid Therapy for Chronic Pain
NCT00656942 ·Status: COMPLETED
-
Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental Pain
NCT00647127 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
NCT00225797 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Opioids on Experimental Hyperalgesia in Oesophagus, Skin and Muscles
NCT00489684 ·Status: COMPLETED
-
Morphine Modulation of The Brain's Pain Matrix
NCT01245244 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance
NCT01681264 ·Status: TERMINATED ·Phase: PHASE4
-
Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia
NCT00418015 ·Status: COMPLETED
-
Comparison of Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia (PCA)
NCT00385541 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain
NCT00365898 ·Status: TERMINATED ·Phase: PHASE3
-
The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers
NCT01886014 ·Status: COMPLETED ·Phase: NA
-
Effect of Ketamine on Opioid-Induced Hyperalgesia
NCT00833755 ·Status: COMPLETED ·Phase: NA
-
Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Chronic Non-cancer Pain
NCT06350786 ·Status: RECRUITING ·Phase: NA
-
Cannabidiol, Morphine, Pain
NCT04030442 ·Status: RECRUITING ·Phase: PHASE1